What's behind the phenomena of chronic pain, and why is it so hard to solve? Compare Inpatient Rehab examined CDC data to ...

President Trump on Wednesday signed an executive order targeting college accreditors, a group of largely unknown but ...

The Shyft Group shares surged 26.2% on Q1 2025 results and Aebi Schmidt merger progress. Read here to know why we recommend a ...

Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ETCompany ParticipantsMatt McQueen - Chief Legal Officer & ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

Lake Street analyst Robert Brown maintained a Buy rating on Chart Industries (GTLS – Research Report) today and set a price target of $225.00. The company’s shares closed yesterday at $133.24.

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Purpose: To examine the issue of pain assessment in infants by acquiring all available published pain assessment tools and evaluating their reported reliability, validity, clinical utility ...

You have the option to change the appearance of the charts by varying the time scale, chart type, zoom and adding your own studies and drawings. You can save your studies and create your own ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company ...